We welcome Karla Childers to AI Uncovered. Karla is a long-standing leader in bioethics and data transparency in the pharmaceutical industry. As part of the Office of the Chief Medical Officer at Johnson & Johnson, she brings deep expertise in navigating the ethical implications of emerging technologies, especially artificial intelligence, in medicine and drug development. In this episode, Tim and Karla explore the intersection of AI, bioethics and patient-centered development. They discu...
All content for AI Uncovered is the property of Timothy Martin, Executive VP of Product at Yseop and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
We welcome Karla Childers to AI Uncovered. Karla is a long-standing leader in bioethics and data transparency in the pharmaceutical industry. As part of the Office of the Chief Medical Officer at Johnson & Johnson, she brings deep expertise in navigating the ethical implications of emerging technologies, especially artificial intelligence, in medicine and drug development. In this episode, Tim and Karla explore the intersection of AI, bioethics and patient-centered development. They discu...
Emmanuel Walckenaer: AI’s Real-World Impact on Pharma & What’s Next in 2025
AI Uncovered
23 minutes
8 months ago
Emmanuel Walckenaer: AI’s Real-World Impact on Pharma & What’s Next in 2025
We’re thrilled to welcome Emmanuel Walckenaer, CEO of Yseop, back to AI Uncovered for a follow-up conversation on the rapid evolution of AI in biopharma. Since his last appearance, the industry has made significant strides in harnessing AI for regulatory submissions, clinical workflows, and medical writing—areas where Yseop is leading the charge in transforming content generation. In this episode, Tim and Emmanuel revisit the biggest AI breakthroughs of 2024 and explore how the pharmace...
AI Uncovered
We welcome Karla Childers to AI Uncovered. Karla is a long-standing leader in bioethics and data transparency in the pharmaceutical industry. As part of the Office of the Chief Medical Officer at Johnson & Johnson, she brings deep expertise in navigating the ethical implications of emerging technologies, especially artificial intelligence, in medicine and drug development. In this episode, Tim and Karla explore the intersection of AI, bioethics and patient-centered development. They discu...
